Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) shares reached a new 52-week high on Thursday after Truist Financial raised their price target on the stock from $25.00 to $33.00. Truist Financial currently has a buy rating on the stock. Edgewise Therapeutics traded as high as $27.51 and last traded at $26.37, with a volume of 2109692 shares trading hands. The stock had previously closed at $19.07.
EWTX has been the subject of several other research reports. JPMorgan Chase & Co. increased their target price on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, August 12th. Piper Sandler reissued an “overweight” rating and set a $48.00 price objective on shares of Edgewise Therapeutics in a report on Monday, July 1st. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a research note on Friday, August 16th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $32.00 price target on shares of Edgewise Therapeutics in a research note on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Edgewise Therapeutics currently has an average rating of “Buy” and a consensus target price of $35.00.
Check Out Our Latest Stock Analysis on EWTX
Hedge Funds Weigh In On Edgewise Therapeutics
Edgewise Therapeutics Stock Down 4.1 %
The company has a market cap of $2.64 billion, a price-to-earnings ratio of -18.25 and a beta of 0.15. The company’s fifty day moving average price is $18.99 and its two-hundred day moving average price is $18.12.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. Research analysts forecast that Edgewise Therapeutics, Inc. will post -1.48 earnings per share for the current year.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Read More
- Five stocks we like better than Edgewise Therapeutics
- How to Invest in Blue Chip Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is the Hang Seng index?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Which Wall Street Analysts are the Most Accurate?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.